Treatment with plasma in non-Stx–HUS patients with CFH and MCP mutations
Episode . | CFH mutation, no. . | MCP mutation, no. . | IF mutation, no. . | P . |
|---|---|---|---|---|
| Treated episodes | 57 (61) | 23 (35) | 6 (8) | < .001 |
| Complete or partial remission | 38 (57) | 21 (23) | 3 (6) | .023 |
| No remission | 19 (57) | 2 (23) | 3 (6) | .023 |
| Nontreated episodes | 4 (61) | 12 (35) | 2 (8) | < .001 |
| Complete or partial remission | 4 (4) | 12 (12) | 1 (2) | .001 |
| No remission | 0 (4) | 0 (12) | 1 (2) | .001 |
Episode . | CFH mutation, no. . | MCP mutation, no. . | IF mutation, no. . | P . |
|---|---|---|---|---|
| Treated episodes | 57 (61) | 23 (35) | 6 (8) | < .001 |
| Complete or partial remission | 38 (57) | 21 (23) | 3 (6) | .023 |
| No remission | 19 (57) | 2 (23) | 3 (6) | .023 |
| Nontreated episodes | 4 (61) | 12 (35) | 2 (8) | < .001 |
| Complete or partial remission | 4 (4) | 12 (12) | 1 (2) | .001 |
| No remission | 0 (4) | 0 (12) | 1 (2) | .001 |
IF mutation group has not been included in statistical analysis. The numbers of patients for whom data were available are reported in parentheses. Plasma treatment includes infusion of 10 to 20 mL/kg/day and/or exchange of 1 to 2 plasma vol/day (or 30-40 mL/kg/day) for a total of 2 to 36 treatments in 2 days to 6 weeks.
P indicates CFH mutation versus MCP mutation. Significant P values are in italics.